Treatment: where are we going?
This chapter deals with problems that lie on the borderline between the pathophysiology, the pharmacotherapy, and the pharmacology of migraine. Our hopes must centre on this border, because an intimate and reliable knowledge of these fields will offer a clue towards an optimal therapeutic strategy. Researchers should concentrate on the drugs that have been developed as alternatives to ergotamine. It is to be hoped that these new drugs will be free of the inherent drawback of ergotamine — its deleterious side-effects when given too frequently. Satisfying results in clinical practice could render the prophylactic treatment of migraine superfluous. It could be a real advantage to avoiding prophylactic treatment, which always has to meet the high standards required of any long-term medication.
Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.